Type 2 diabetes
Conditions
Interventions
60 min postprandial blood withdrawal Test drug (mosapride citrate) 15mg/day for 2 weeks 60 min postprandial blood withdrawal Washout period (4-8 weeks) 60 min postprandial blood withdrawal Compar
Sponsors
Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type 2 diabetic patients 2) Glycoalbmin < 26.0 % 3) BMI < 30.0 4) Patient explained and informed with the written consent
Exclusion criteria
Exclusion criteria: 1) Type 1 diabetic patients 2) Patient with a history of diabetic coma within 6 months 3) Necessity of insulin such as severe infection, perioperative period, and severe external injury 4) Severe hepatic and renal disorder (Ccr < 30mL/min, serum Cre > 2.0 mg/dl (female), 2.5 mg/dl (male), Child-Pugh grade C) 5) Severe gastrointestinal dysfunction 6) Patient administrated drugs with the same indications of test drug or comparative drug, insulin GLP-1 analog, or DPP4 inhibitor, or treated by 4 or more diabetes drug 7) Pregnant female, lactating female, or female with possibility or planning of pregnancy 9) Patients evaluated incompetent by doctors in attendance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference between 2 groups' amount of 60 minutes postprandial plasma active GLP-1 change after 2 weeks administration of test drug or comparative drug from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference of 60 minutes postprandial plasma active GLP-1 change between before and after 2 weeks administration of test drug or comparative drug and difference between 2 groups' of glycoalbmin, 60 minutes postprandial insulin, glucose, HOMA-R, HOMA-beta, and frequency of stool | — |
Countries
Japan
Contacts
Public ContactDaisuke Maruoka
Chiba University Hospital Gastroenterology
Outcome results
None listed